Infants protected by vaccines from HIV, illustration.

Vaccine Timing: How Early Intervention Can Protect HIV-Exposed Infants

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"New research highlights the critical window for antiretroviral therapy to bolster immunity in vulnerable children."


Vaccines are a cornerstone of public health, safeguarding us against a host of infectious diseases. For infants, especially those exposed to HIV, the timing of these vaccinations can be crucial. A recent study published in Expert Review of Vaccines sheds light on how early intervention with antiretroviral therapy (ART) can shape the immune response to routine childhood vaccines in HIV-exposed and HIV-infected children.

HIV infection can disrupt the normal development of the immune system, potentially weakening the response to vaccines. This is particularly concerning for infants born to HIV-infected mothers, who may be exposed to the virus in utero or during breastfeeding. Early initiation of ART can help to restore immune function, but the optimal timing for this intervention has been a subject of ongoing research.

The study, conducted by researchers in South Africa, investigated the impact of ART timing on the immune memory responses to common childhood vaccines, including those for diphtheria, tetanus, pertussis, and hepatitis B. By comparing HIV-unexposed, HIV-exposed but uninfected, and HIV-infected children, the researchers aimed to identify the most effective strategies for protecting this vulnerable population.

AI Search Multiple angles on this topic

Vaccination Guidance and Timing

U.S. guidance provides routine childhood vaccine recommendations for children with HIV from birth through age 18. The CDC's VaxView program reports vaccination coverage for routinely recommended vaccines among children ages 19 through 35 months. These coverage data are available nationally and through local areas, states, and HHS regions via the National Immunization Survey-Child.

Guidelines and Clinical Timing

CDC HIV guidance was updated in response to new medication options, new information about the detection windows of different HIV tests, and evidence concerning transmission from people with undetectable viral loads. NIH guidance addresses postpartum treatment of newborns who were perinatally exposed to HIV. Research has also examined how HIV exposure and the timing of antiretroviral therapy initiation affect immune responses to live-attenuated trivalent oral poliovirus vaccine.

From HIV/AIDS to HEU Research

The HIV.gov timeline follows the history of HIV and AIDS in the United States from the first reported cases in 1981 to the present. It presents significant events and milestones in the fight against HIV/AIDS. The scale-up of combination antiretroviral therapy during pregnancy has substantially reduced vertical HIV transmission and contributed to a growing population of infants who are HIV-exposed but uninfected.

The Study: How ART Timing Impacts Vaccine Response?

Infants protected by vaccines from HIV, illustration.

The study involved a cohort of children who were part of a larger trial examining the effects of early ART initiation on HIV-infected infants. The children were divided into three groups:

The researchers measured antibody levels for various vaccine-preventable diseases at different time points: before a booster dose of DTwP (diphtheria-tetanus-whole cell pertussis) vaccine, shortly after the booster, and at 24 months of age. This allowed them to assess both the initial response to the vaccine and the persistence of immune memory over time.

  • HIV-unexposed: Children born to mothers without HIV.
  • HIV-exposed uninfected (HEU): Children born to HIV-infected mothers but who did not themselves contract the virus.
  • HIV-infected: Children who were infected with HIV and randomized to start ART either immediately (ART-Immed) or when clinically indicated (ART-Def).
AI Search Multiple angles on this topic

What Recent Studies Show

A Western Kenya study followed 85 HIV-exposed uninfected children and 168 HIV-unexposed uninfected children from birth through 24 months. All mothers living with HIV in that study received combination antiretroviral therapy. Recent reviews describe reported immune defects in HIV-exposed uninfected infants involving pathogen sensing and recognition, oxidative burst, and antigen-specific responses. A 2017 study of BCG vaccination examined timing that could reduce HIV transmission risks while preserving potential benefits.

Unresolved Timing Questions

It remains unclear whether giving BCG very early in life provides adequate protection against tuberculosis and other infections among HIV-1-exposed children. This uncertainty is important because even HIV-1-exposed children who remain uninfected may show impaired immunocompetence early in infancy. Evidence limitations also matter: one study lacked maternal and baseline birth-infant data, while another used an ELISA comparison for polio-specific IgA without access to the gold-standard oral poliovirus vaccine neutralization assay.

Early Versus Delayed BCG

Research has evaluated delayed BCG vaccination strategies in HIV-exposed infants. A planned comparison was designed to assess immune cells and responses to tuberculosis and other vaccines, as well as immune activation and disease progression among infants who became HIV-infected in the BCG or control arms. In one report, delaying BCG rather than administering it at birth did not produce a statistically significant difference in plasma inflammatory cytokine concentrations, including IL-13 and interferon-alpha.

Antibody levels were assessed for pertussis-toxoid, filamentous hemagglutinin (FHA), diphtheria-toxoid, tetanus-toxoid, and hepatitis B. Researchers analyzed the data to determine how ART timing affected antibody levels and the ability to maintain protective immunity.

Protecting Future Generations: The Importance of Continued Research

This study underscores the importance of early ART initiation in HIV-infected infants to optimize their response to routine childhood vaccines. By providing timely access to treatment, we can help to strengthen their immune systems and protect them from potentially life-threatening infections. Continued research is needed to further refine ART strategies and ensure that all children, regardless of their HIV status, have the opportunity to thrive.

AI Search Multiple angles on this topic

Designing Infant HIV Vaccines

There is a strong rationale for developing an HIV vaccine tailored to provide protection early in life. Several adjuvants have already been assessed in early-phase clinical studies. This research direction focuses on creating adjuvanted infant HIV vaccines for early-life protection.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is antiretroviral therapy and why is it so important for infants exposed to HIV?

Antiretroviral therapy, or ART, is a treatment that uses medicines to combat HIV infection. While it cannot cure HIV, ART can control the virus, enabling individuals with HIV to live longer and healthier lives, and it also reduces the risk of HIV transmission. In the context of HIV-exposed infants, early initiation of ART is crucial because it helps to restore and strengthen the infant's immune system, which may have been compromised due to exposure to HIV in utero or during breastfeeding. This early intervention is vital for improving their response to routine childhood vaccines and protecting them from opportunistic infections. Without ART, HIV-infected infants are at high risk of developing AIDS and other life-threatening conditions.

2

Could you explain what vaccines are and why they matter, especially for babies who might have been exposed to HIV?

Vaccines are biological preparations that provide active acquired immunity to a particular infectious disease. Vaccines contain an agent that resembles a disease-causing microorganism and are often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. Vaccines are critical for public health because they help prevent the spread of infectious diseases by stimulating the body's immune system to produce antibodies that recognize and fight off specific pathogens. In HIV-exposed infants, vaccines may be less effective due to the potential disruption of their immune system, making early interventions like ART even more important to ensure they develop adequate protection against vaccine-preventable diseases.

3

What does it mean for a baby to be HIV-exposed but uninfected, and why should we still be concerned about their health?

An HIV-exposed uninfected infant, or HEU, is a child born to an HIV-infected mother who does not contract the virus themselves. These infants are still considered a vulnerable population because they may have been exposed to HIV in utero or during breastfeeding, which can affect their immune system development. Although HEU infants do not have HIV, their immune response to vaccines and their overall health outcomes can differ from those of children born to HIV-negative mothers. Research, such as studies on the timing of ART, is important to understand the best strategies for protecting the health of HEU infants and ensuring they respond well to routine vaccinations. They may require closer monitoring and tailored vaccination schedules to optimize their immune responses.

4

What is the DTwP vaccine, and why is it important to measure antibody levels related to it?

The DTwP vaccine is a combination vaccine that protects against three infectious diseases: diphtheria, tetanus, and pertussis (whooping cough). It is a routine childhood vaccine administered in multiple doses to provide comprehensive protection against these potentially life-threatening illnesses. Diphtheria and tetanus are caused by bacteria that produce toxins, while pertussis is a highly contagious respiratory infection. The 'wP' refers to the whole-cell pertussis component. Assessing antibody levels after DTwP vaccination, as performed in the study, is important to determine if children have developed adequate immunity. Monitoring the levels before and after booster doses helps to understand the initial response and the persistence of immune memory over time. This vaccine is crucial in preventing these diseases and safeguarding children's health.

5

Why is it important to monitor antibody levels in children, especially in the context of HIV exposure and vaccination?

Antibody levels are the concentration of specific antibodies present in the blood, which are proteins produced by the immune system in response to an antigen, such as a vaccine or an infection. Measuring antibody levels is important because it indicates the strength of a person's immune response to a particular pathogen or vaccine. High antibody levels generally suggest a strong and protective immune response, while low levels may indicate a need for booster shots or a compromised immune system. In studies involving HIV-exposed infants, monitoring antibody levels after vaccination helps researchers understand how well the infants' immune systems respond to vaccines and how the timing of interventions like ART affects their ability to develop protective immunity. Consistently low antibody levels can leave individuals vulnerable to infections, emphasizing the importance of achieving and maintaining adequate levels through effective vaccination strategies.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.